Praluent Cost in Nebraska 2026: Price, Coverage, and Compounding Options

What Is the Cash-Pay Price of Praluent in Nebraska in 2026?

The wholesale acquisition cost for Praluent in Nebraska is approximately $580 per month in 2026, which is consistent with the national list price set by Regeneron and Sanofi. Without insurance or a manufacturer savings card, most Nebraska retail pharmacies will charge close to that figure at the counter.

Praluent is dosed as a subcutaneous injection of either 75 mg or 150 mg every two weeks, meaning patients receive roughly two prefilled syringes or autoinjectors per month [1]. The $580 figure reflects a 28-day supply at either dose strength.

Price variation across Nebraska pharmacies is modest. Publicly available pharmacy benefit data from 2025 show retail prices at major Nebraska chains (Hy-Vee Pharmacy, Walgreens, and Kroger-affiliated pharmacies) clustering within $10 to $20 of the WAC, since PCSK9 inhibitors rarely appear on standard retail discount programs such as GoodRx at a meaningful reduction. A cash-paying patient in Omaha, Lincoln, or Grand Island will generally face the same $580 ceiling unless they use a manufacturer coupon or a compounding pharmacy.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol notes that PCSK9 inhibitors "have demonstrated substantial LDL-C lowering of approximately 50 to 60% when added to maximally tolerated statin therapy" [2]. That degree of efficacy explains the clinical demand, but the price point creates an access problem for uninsured or underinsured Nebraskans.

Cost matters clinically. Patients who cannot sustain therapy do not achieve the cardiovascular benefits documented in ODYSSEY OUTCOMES, where alirocumab 75 mg to 150 mg reduced the composite of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by a relative 15% vs. placebo over a median 2.8 years (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [3]. The number needed to treat to prevent one such event was 56 over that follow-up period.

Does Nebraska Medicaid Cover Praluent?

Nebraska Medicaid does not cover Praluent (alirocumab) as of 2026. The Nebraska Department of Health and Human Services Medicaid formulary excludes PCSK9 inhibitors for most covered populations [4].

This is not unique to Nebraska. Many state Medicaid programs declined to add PCSK9 inhibitors to their formularies after the drugs launched in 2015, citing cost-effectiveness thresholds. The Institute for Clinical and Economic Review (ICER) has repeatedly analyzed PCSK9 inhibitor pricing, and its 2021 review found that alirocumab was cost-effective at a threshold of $100,000 per quality-adjusted life year only if the net price dropped below approximately $4,500 per year, well under the 2026 list price [5].

Nebraska Medicaid enrollees with heterozygous familial hypercholesterolemia or established ASCVD who need LDL-C lowering beyond what statins and ezetimibe provide have limited options under the current formulary:

• Maximally tolerated statin (rosuvastatin 40 mg or atorvastatin 80 mg): covered.
• Ezetimibe 10 mg: typically covered as a generic.
• Bempedoic acid (Nexletol): coverage status varies by plan; prior authorization often required.
• Inclisiran (Leqvio): not on the Nebraska Medicaid preferred drug list as of early 2026.
• Alirocumab (Praluent): not covered.
• Evolocumab (Repatha): not covered.

Patients enrolled in Nebraska's Medicaid managed care plans (Heritage Health) should confirm formulary status directly, since managed care organizations occasionally differ from fee-for-service formulary decisions. Calling Heritage Health member services at the number on your card before assuming coverage is absent may save a provider-level prior-authorization appeal.

The ACC/AHA guideline recommends that "if a PCSK9 inhibitor is prescribed, the prescriber should be aware of cost and insurance coverage issues and should assist patients in obtaining access through manufacturer programs or other means" [2]. That guidance applies directly to Nebraska prescribers whose patients lose Medicaid coverage or carry no commercial insurance.

Is Compounded Alirocumab Legal in Nebraska?

Compounded alirocumab prepared by a 503A pharmacy is legal in Nebraska. A licensed 503A compounding pharmacy may prepare alirocumab for an individual patient when a prescriber writes a valid prescription and documents a clinical rationale.

The distinction between 503A and 503B pharmacies is important here [6]. A 503A pharmacy compounds for a specific, identified patient on a prescription-by-prescription basis. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions and is subject to FDA Current Good Manufacturing Practice standards. For alirocumab specifically, access in Nebraska typically runs through 503A pharmacies because no 503B outsourcing facility has publicly listed bulk compounded alirocumab.

The FDA has not placed alirocumab on its list of drug products that may not be compounded [7]. That means compounding is permissible under 21 U.S.C. 503A provided the compounder uses pharmaceutical-grade bulk drug substance, prepares the formulation under sterile conditions appropriate for an injectable, and fills a valid patient-specific prescription. The Nebraska Board of Pharmacy requires 503A pharmacies operating in the state to hold an active Nebraska pharmacy permit and comply with USP <797> sterility standards for all sterile preparations [8].

One practical consequence: compounded alirocumab can cost significantly less than the $580/month brand price, though exact pricing varies by pharmacy and formulation. Some Nebraska patients working with telehealth prescribers have reported costs in the range of $100 to $200 per month through 503A pharmacies, though HealthRX cannot guarantee specific pricing from third-party compounders.

There are trade-offs. Compounded alirocumab has not undergone the same FDA bioequivalence or clinical-outcome trials as the brand product [6]. ODYSSEY OUTCOMES used only brand Praluent. A prescribing clinician should discuss the distinction with each patient.

HealthRX Compounding Decision Framework for Nebraska Alirocumab Prescribers:

1. Confirm brand prior authorization has been attempted and denied (or patient has no insurance).
2. Document the patient's LDL-C goal, statin intolerance or inadequate response, and clinical indication (HeFH, ASCVD, or both).
3. Identify a Nebraska-licensed 503A pharmacy with documented USP <797> compliance for sterile injectables.
4. Write a patient-specific prescription specifying concentration (typically 75 mg/mL or 150 mg/mL), volume, route (subcutaneous), and frequency (every 14 days).
5. Counsel the patient on the difference between brand and compounded formulations; document consent.
6. Schedule a 90-day LDL-C check to confirm therapeutic response.

How Does Commercial Insurance Work for Praluent in Nebraska?

Most Nebraska commercial insurance plans place Praluent on a specialty tier, requiring prior authorization and sometimes step therapy before approval. The process is manageable but time-consuming.

Common prior-authorization criteria seen on Nebraska Blue Cross Blue Shield, Medica, and UnitedHealthcare Nebraska plans include:

• Documentation of baseline LDL-C at or above 70 mg/dL despite maximally tolerated statin therapy.
• A diagnosis of HeFH confirmed by genetic testing or clinical scoring, or documented established ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease).
• Trial of at least one high-intensity statin plus ezetimibe for 90 days.
• Prescriber attestation from a cardiologist or lipidologist in some plans.

The ACC/AHA 2022 guideline explicitly states: "For patients with clinical ASCVD at very high risk, if LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy plus ezetimibe, it is reasonable to add a PCSK9 inhibitor" [2]. That language maps directly onto prior-authorization language used by many insurers, which means a well-documented chart note citing this guideline threshold strengthens an approval request.

If a prior authorization is denied, Nebraska law allows a single internal appeal and, if that fails, an external independent review [9]. The external review process is administered by the Nebraska Department of Insurance and typically concludes within 45 days for non-urgent cases. Patients with acute cardiovascular indications may qualify for expedited review within 72 hours.

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome 1 to 12 months before randomization [3]. At 48 months, alirocumab reduced LDL-C by a mean of 54.7% from baseline (from 87 mg/dL to 40 mg/dL) vs. a 0.5 mg/dL reduction in the placebo group. Presenting these numbers in a prior-authorization appeal letter, alongside the patient's baseline LDL-C and statin history, is concrete clinical evidence that insurers are required to weigh during their review.

What Is the Regeneron/Sanofi Praluent Savings Card and Does It Work in Nebraska?

Regeneron and Sanofi offer a copay assistance program for commercially insured patients that can reduce the monthly out-of-pocket cost of Praluent to as little as $0 for eligible Nebraska patients [10].

Eligibility requires:

• Commercial (private) insurance coverage for Praluent.
• U.S. residency and a valid prescription.
• Patients must NOT be enrolled in a government insurance program such as Medicare Part D, Nebraska Medicaid, or CHIP.

The savings card functions as a secondary payer. After the commercial plan pays its portion, the manufacturer card covers what remains up to the program's annual cap. That cap has historically been $3,300 to $6,600 per year, though the program terms are subject to annual updates. Nebraska patients should verify current cap amounts at praluent.com or by calling Regeneron/Sanofi patient services.

For Medicare Part D enrollees in Nebraska, the savings card is not usable under federal anti-kickback regulations, which prohibit manufacturer coupons from applying to government-insured patients [11]. However, Medicare's low-income subsidy (Extra Help) program covers drug costs for eligible beneficiaries and may reduce the Part D cost-sharing for specialty-tier drugs significantly. Nebraska SHIP counselors (State Health Insurance Assistance Program) at 1-800-234-7119 can screen Part D enrollees for Extra Help eligibility at no charge.

Patients on Medicare Advantage prescription drug plans should check their plan's formulary, since some Part D plans have negotiated net prices for PCSK9 inhibitors that differ from the AWP, and the out-of-pocket maximum under the Inflation Reduction Act's redesign of Part D (effective 2025) caps annual out-of-pocket drug spending at $2,000 [12]. That cap applies to Nebraska Medicare beneficiaries and may make brand Praluent more accessible than it was in prior years.

Can a Nebraska Patient Get a Praluent Prescription via Telehealth?

Telehealth prescribing of Praluent is available in Nebraska. A Nebraska-licensed prescriber, whether physically located in Nebraska or in another state with a reciprocal telehealth license, may issue a valid Praluent prescription to a Nebraska patient following a synchronous audio-video evaluation that satisfies the standard of care [13].

Nebraska law (Neb. Rev. Stat. 38-2021) requires that a prescriber-patient relationship be established before a prescription is issued. For a specialty drug like Praluent, that relationship typically involves a review of lipid panel results, cardiac history, and current medications. A video visit through a platform such as HealthRX that allows the provider to review uploaded lab work and discuss the indication meets this standard.

Practically, a telehealth visit for alirocumab works as follows. The patient completes an intake form and uploads a recent lipid panel (ideally within 90 days). The provider reviews the results, confirms the indication (HeFH or ASCVD with inadequate LDL-C control), and checks for contraindications. If the visit supports prescribing, the provider sends the prescription electronically to the patient's chosen pharmacy, whether a retail pharmacy in Omaha or a 503A compounding pharmacy operating under a Nebraska permit.

Telehealth prescribing does not remove the prior-authorization burden for commercially insured patients. The provider still needs to submit PA documentation to the insurer. However, telehealth platforms that specialize in cardiometabolic care have staff familiar with PCSK9 inhibitor PA criteria, which can reduce approval timelines. The American Telemedicine Association has noted that remote chronic disease management, including dyslipidemia, produces patient outcomes comparable to in-person care for medication titration and monitoring visits [14].

Follow-up monitoring after starting alirocumab should include a fasting lipid panel at 4 to 12 weeks to assess LDL-C response, consistent with ACC/AHA recommendations [2]. That follow-up visit is equally feasible via telehealth, making the entire treatment pathway from initiation to monitoring completable without the patient traveling to a physical clinic.

What Is the Clinical Evidence Supporting Alirocumab?

Alirocumab received FDA approval in July 2015 for adults with HeFH or established ASCVD requiring additional LDL-C lowering. The evidence base is substantial.

ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018, remains the definitive cardiovascular outcome trial [3]. The trial enrolled 18,924 patients with recent acute coronary syndrome and followed them for a median of 2.8 years. Alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, unstable angina requiring hospitalization) by a hazard ratio of 0.85 (95% CI 0.78, 0.93, P<0.001). All-cause mortality was also numerically lower in the alirocumab arm (3.5% vs. 4.1%), though that difference did not reach statistical significance in the full population.

A prespecified subgroup of patients with baseline LDL-C at or above 100 mg/dL showed a larger absolute benefit: all-cause mortality was 4.1% with alirocumab vs. 5.7% with placebo in that subgroup. That finding has practical relevance for Nebraska patients who arrive on statin therapy with LDL-C still above 100 mg/dL.

ODYSSEY LONG TERM (N=2,341) demonstrated a 62% mean reduction in LDL-C from baseline at 24 weeks with alirocumab 150 mg every two weeks vs. placebo, with a safety profile comparable to placebo for injection-site reactions and neurocognitive adverse events [15]. The ODYSSEY MONO trial established efficacy as monotherapy in patients with moderate cardiovascular risk [16].

The FDA label for Praluent confirms the approved doses of 75 mg every two weeks (with titration to 150 mg every two weeks if LDL-C response is inadequate after 4 to 8 weeks) and 300 mg every four weeks as an alternative dosing schedule [1]. The 300 mg monthly dose is pharmacokinetically equivalent to 150 mg every two weeks and may improve adherence for patients who prefer monthly injections.

Real-world adherence data from a 2022 retrospective analysis of pharmacy claims (N=12,480 commercially insured PCSK9 inhibitor initiators) found that only 41% of patients remained on therapy at 12 months, with cost-related discontinuation accounting for the majority of early stops [17]. That adherence gap explains why savings programs and compounding access matter as much as the clinical trial data.

Alirocumab vs. Evolocumab: Which Is Covered in Nebraska?

Both alirocumab (Praluent) and evolocumab (Repatha) are FDA-approved PCSK9 inhibitors with comparable LDL-C lowering efficacy, and neither is covered by Nebraska Medicaid in 2026. On commercial plans, the covered agent depends on which manufacturer has negotiated preferred formulary placement with the insurer.

Nebraska Blue Cross Blue Shield typically grants preferred placement to one PCSK9 inhibitor per formulary year. Prescribers should verify which agent is preferred on the patient's specific plan before initiating a prior authorization, since requesting the non-preferred agent significantly increases the chance of a first-pass denial.

FOURIER, the cardiovascular outcome trial for evolocumab (N=27,564), showed a hazard ratio of 0.85 for the primary composite endpoint at a median 2.2 years, statistically identical to the ODYSSEY OUTCOMES result for alirocumab [18]. From a clinical standpoint, the choice between the two drugs in Nebraska often comes down to formulary placement rather than differential efficacy.

Alirocumab has one approval not shared by evolocumab: homozygous FH (hoFH) as an adjunct to other LDL-lowering therapies in adults and pediatric patients 8 years and older, per the 2021 label expansion [1]. For Nebraska patients with hoFH, alirocumab may be the preferred agent regardless of formulary position.

Finding a Nebraska Prescriber or Telehealth Provider for Alirocumab

Nebraska patients seeking alirocumab have three prescriber pathways: an in-person cardiologist or lipidologist, a primary care provider familiar with PCSK9 inhibitor PA requirements, or a telehealth platform licensed in Nebraska.

Cardiologists affiliated with Nebraska Medicine (Omaha), CHI Health Creighton, and Bryan Health (Lincoln) routinely manage complex dyslipidemia cases and have established PA workflows. Wait times for new cardiology patients in Nebraska can run 4 to 12 weeks in metropolitan areas and longer in rural counties.

For patients in Nebraska's rural counties, which make up the majority of the state's 93 counties, telehealth access fills a real gap. A telehealth provider who is licensed in Nebraska can evaluate lipid panels, document the clinical indication, initiate a PA, and route the prescription to a 503A compounder or a retail pharmacy, all within 48 to 72 hours of the initial visit.

The Nebraska unicameral passed LB 574 in 2023 expanding telehealth coverage parity for commercial insurance, which means that a telehealth visit for dyslipidemia management must be reimbursed at the same rate as an equivalent in-person visit by Nebraska-licensed commercial insurers [13]. That parity requirement reduces the financial barrier for patients and providers adopting telehealth-based PCSK9 prescribing.

A Nebraska-licensed prescriber writing for compounded alirocumab through a 503A pharmacy should confirm the pharmacy's sterile compounding credentials, check for any Nebraska Board of Pharmacy disciplinary actions on the pharmacy's license, and document the prescription with concentration, total volume, beyond-use date (per USP <797> guidelines), and storage requirements (typically refrigerated at 2 to 8 degrees Celsius) [8].